These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 3519563)

  • 1. Is there a role for monotherapy with beta-lactam antibiotics in the initial empirical management of febrile neutropenic cancer patients?
    Hathorn JW; Pizzo PA
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():41-54. PubMed ID: 3519563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
    DeJace P; Klastersky J
    Am J Med; 1986 Jun; 80(6B):29-38. PubMed ID: 3524218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical therapy for bacterial infections in neutropenic patients.
    Klastersky J
    Support Care Cancer; 1994 Nov; 2(6):347-54. PubMed ID: 7858926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of aminoglycosides in neutropenic patients.
    Cometta A; Glauser MP
    Schweiz Med Wochenschr Suppl; 1996; 76():21S-27S. PubMed ID: 8677415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy and monotherapy in the treatment of severe infection in the immunocompromised host.
    Gaya H
    Am J Med; 1986 Jun; 80(6B):149-55. PubMed ID: 3728525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is double coverage of gram-negative organisms necessary?
    Johnson SJ; Ernst EJ; Moores KG
    Am J Health Syst Pharm; 2011 Jan; 68(2):119-24. PubMed ID: 21200057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of empiric antibiotic therapy for the febrile neutropenic patient.
    Schimpff SC
    Rev Infect Dis; 1985; 7 Suppl 4():S734-40. PubMed ID: 3878564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The results of a randomized trial of empirical antibiotic treatment in febrile neutropenic patients with four beta-lactam/aminoglycoside combinations.
    Hann I; Noone P; Prentice HG; Sage R; Blacklock H; Stirling L; Gray R; Corringham R; Boesen E; Mohiuddin J
    J Antimicrob Chemother; 1983 May; 11 Suppl C():57-63. PubMed ID: 6352605
    [No Abstract]   [Full Text] [Related]  

  • 11. Combating infections in neutropenic patients.
    Pizzo PA
    Hosp Pract (Off Ed); 1989 Jul; 24(7):93-100, 103-4, 107-10. PubMed ID: 2501330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
    Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
    Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of gram-positive therapy in the neutropenic patient.
    Menichetti F; Del Favero A
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():51-60. PubMed ID: 1829077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ureidopenicillins, aztreonam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy.
    Winston DJ; Ho WG; Champlin RE; Gale RP; Busuttil RW
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():55-66. PubMed ID: 3086277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A; Bucaneve G; Menichetti F
    Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent therapy for infections in neutropenic cancer patients.
    Fainstein V; Bodey GP
    Am J Med; 1985 Aug; 79(2A):83-8. PubMed ID: 3895923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging cephalosporins.
    Page MG
    Expert Opin Emerg Drugs; 2007 Nov; 12(4):511-24. PubMed ID: 17979596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management in the febrile, neutropenic patient with cancer: therapeutic considerations.
    Brown AE
    J Pediatr; 1985 Jun; 106(6):1035-42. PubMed ID: 3889253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.